Madrigal Pharmaceuticals Inc MDGL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $471.32
- Day Range
- $460.89–478.78
- 52-Week Range
- $275.00–615.00
- Bid/Ask
- $362.64 / $478.30
- Shares Outstanding
- 23.06M
- Market Cap
- $10.93B
- Volume/Avg
- 596 / 311,832
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.55
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.06%
Company Profile
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 915
- Website
- https://www.madrigalpharma.com
Valuation
|
Metric
|
MDGL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 20.24 |
Price/Sales | 9.55 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MDGL
|
|---|---|
Quick Ratio | 2.96 |
Current Ratio | 3.50 |
Interest Coverage | −11.88 |
Quick Ratio
MDGL
Profitability
|
Metric
|
MDGL
|
|---|---|
Return on Assets (Normalized) | −16.67% |
Return on Equity (Normalized) | −30.74% |
Return on Invested Capital (Normalized) | −22.95% |
Return on Assets
MDGL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Kbfgtrgt | Qqhwbq | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yvtyjxxs | Rcfryv | $64B | |||
| argenx SE ADR
ARGX
| Lsjrwcgxn | Mxbyk | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hhjhfhwj | Fyshbs | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Vfxynfgbcn | Bjswhxx | $24B | |||
| BioNTech SE ADR
BNTX
| Xbgwwvmw | Zbkl | $23B | |||
| Incyte Corp
INCY
| Tldhcpfg | Fdmt | $22B | |||
| Moderna Inc
MRNA
| Nhhvbdm | Slhx | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Jwbdmfys | Xkr | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Fxvlgxlb | Phyhl | $13B |
United States